Article Information
History
- November 22, 2022.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Hsiangkuo Yuan1,†,
- Aniket Natekar2,†,
- Jade S. Park3,
- Clinton Lauritsen1,
- Eugene R. Viscusi4 and
- Michael J. Marmura1,*
- 1Jefferson Headache Center, Department of Neurology, Thomas Jefferson University, Philadelphia, PA, USA
- 2OhioHealth Physician Group, Columbus, OH, USA
- 3Department of Neurology, Rush University, Chicago, IL, USA
- 4Department of Anesthesiology, Thomas Jefferson University, Philadelphia, PA, USA
- ↵*Correspondence: Michael J. Marmura, MD; Michael.marmura{at}jefferson.edu, Jefferson Headache Center, Department of Neurology, Thomas Jefferson University, 900 Walnut Street, Suite 200, Philadelphia, PA 19107, (215) 955-2243
Posted November 22, 2022.
Real-world study of intranasal ketamine for use in patients with refractory chronic migraine
